Bristol-Myers Squibb CoBMY:NYQ

50.64
0.84 / 1.69%
2.18m
15.72%
0.4213
Latest price in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 29 2014 15:31 BST.

Search 136 articles on Bristol-Myers Squibb Co

Drug cocktails point the way towards relief for all hepatitis C sufferers
Hepatitis C researchers battle to 'nuke' the competition
Eli Lilly joins forces with UK biotech to develop cancer drugs
Shire Pharmaceuticals spells out plans to double revenues by 2020
Hepatitis C: Gilead's Odyssey
AstraZeneca seeks to bring new cancer drugs to market
GlaxoSmithKline in oncology push with $350m UK biotech deal
Hopes for cancer cures offer comfort for battered pharma
AstraZeneca to showcase emerging drugs behind Pfizer rejection
Pfizer-AstraZeneca marriage divides opinion

Reuters News Service company announcements are delayed by up to one hour.

© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.